LAGUNA NIGUEL, Calif. — A drug maker that focuses on treatments for hemophilia has named a new CEO.
Inspiration Biopharmaceuticals announced Tuesday the appointment of John Butler as chief executive officer. Butler replaces Michael Griffith, who is taking the role of chief scientific officer while retaining the title of president.
Butler previously worked at Genzyme, which French drug maker Sanofi acquired in April. There, he served as president of the company's rare genetic diseases business and also led its renal, endocrinology and cardiovascular businesses. Before that, he worked in sales and marketing for Amgen and Hoffmann-La Roche.